Pardeep Heir
Pardeep Heir
Biography
Pardeep Heir practises intellectual property law with an emphasis on pharmaceutical patent litigation. His experience includes patent infringement and validity matters as well as damages matters under section 8 of the Patented Medicines (Notice of Compliance) Regulations. He has been involved in patent litigation disputes related to a range of pharmaceutical products, including small molecules, recombinant proteins, monoclonal antibodies and gene therapy vectors.
Dr. Heir joined our Toronto office as a summer student in 2018 and returned to article with us in 2019-2020. During his articles, Dr. Heir was seconded to a leading multinational pharmaceutical company where he gained valuable experience with commercial, employment, intellectual property and regulatory matters.
Before his legal career, Dr. Heir worked as a scientific associate at a cancer research centre. Dr. Heir's research has been published in peer-reviewed scientific journals, and he has presented his research at international scientific conferences.
Professional experience
Auszeichnungen
Auszeichnungen
- Canadian Law Awards 2022, Commercial Litigation Case of the Year Excellence Awardee for Pharmascience Inc. v. Pfizer Canada ULC
Ausbildung
Ausbildung
J.D., University of Toronto, 2019
Ph.D., University of Toronto, 2015
B.Sc. (Hons.), York University, 2008
Zulassungen
Zulassungen
- Ontario 2020
Publikationen
Publikationen
- Co-author, "c-Src Phosphorylates and Inhibits the Function of the CIC Tumor Suppressor Protein," Molecular Cancer Research, 2020
- Co-author, "CIC protein instability contributes to tumorigenesis in glioblastoma," Nature Communications, 2019
- First author, "Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling," The Journal of Biological Chemistry, 2016
- First author, "Hydroxylation-Dependent Interaction of Substrates to the Von Hippel-Lindau Tumor Suppressor Protein (VHL)," Methods in Molecular Biology, 2016
- Co-author, "Inhibition of SHP2-mediated dephosphorylation of Ras suppresses oncogenesis," Nature Communications, 2015
- Co-author, "Juvenile myelomonocytic leukaemia-associated mutation in Cbl promotes resistance to apoptosis via the Lyn-PI3K/AKT pathway," Oncogene, 2015
- Co-author, "Src promotes GTPase activity of Ras via tyrosine 32 phosphorylation," Proceedings of the National Academy of Sciences of the United States of America, 2014
- Co-author, "SOCS-1 mediates ubiquitylation and degradation of GM-CSF receptor," PLoS One, 2013
- First author, "DCNL1 functions as a substrate sensor and activator of cullin 2-RING ligase," Molecular and Cellular Biology, 2013
- Co-author, "Hypoxia promotes ligand-independent EGF receptor signaling via hypoxia-inducible factor-mediated upregulation of caveolin-1," Proceedings of the National Academy of Sciences of the United States of America, 2012
- Co-author, "Loss of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin ligase underlies Chuvash polycythemia," Nature Medicine, 2011
- Co-author, "Deregulation of E2-EPF ubiquitin carrier protein in papillary renal cell carcinoma," The American Journal of Pathology, 2011
Insights and news
